Company Overview of Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. engineers antibody-drug conjugates that maximize the potential of new and established therapeutic classes. The company develops a portfolio of antibody-drug conjugates to improve patient outcomes in multiple oncology indications. Its clinical-stage product candidates include XMT-1001, a “tecan” conjugate for patients with lung cancers; and XMT-1107, an anti-angiogenic conjugate for patients with refractory, advanced solid tumors. The company’s conjugation system provides benefits for the development of drugs across therapeutic modalities, including antibody-drug conjugates, antibody fragments, small molecules, biologics, and synergistic drug combinations. Mersana T...
840 Memorial Drive
Cambridge, MA 02139
Founded in 2001
Key Executives for Mersana Therapeutics, Inc.
Chief Executive Officer, President and Director
Vice President of Finance
Compensation as of Fiscal Year 2015.
Mersana Therapeutics, Inc. Key Developments
Mersana Therapeutics and Takeda Pharmaceutical Company Limited Enter into New Strategic Partnership
Feb 3 16
Harris & Harris Group, Inc. noted the announcement by its portfolio company, Mersana Therapeutics, that Mersana and Takeda Pharmaceutical Company Limited have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana’s Fleximer® antibody-drug conjugate (ADC) platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs. XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumors, including breast, gastric and non-small cell lung cancers. Mersana will receive an upfront payment of $40 million and an additional payment of $20 million upon clearance of the IND (Investigational New Drug application) for XMT-1522 by the FDA. Subject to the success of the XMT-1522 and ADC programs, Mersana is eligible to receive milestone payments of more than $750 million combined, as well as royalties.
Mersana Therapeutics, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:15 PM
Sep 25 15
Mersana Therapeutics, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:15 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Anna Protopapas, Chief Executive Officer, President and Director.
Mersana Therapeutics, Inc. Presents at 22nd Annual NewsMakers in the Biotech Industry Investment Conference, Sep-10-2015 01:30 PM
Aug 8 15
Mersana Therapeutics, Inc. Presents at 22nd Annual NewsMakers in the Biotech Industry Investment Conference, Sep-10-2015 01:30 PM. Venue: Millennium Broadway Hotel & Conference Center - Breakout Room 401, 145 West 44th Street, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 20, 2015